Parion Sciences Announces Publication of Phase 2 CLEAN-PCD Study in The Lancet Respiratory Medicine
September 08, 2023 09:00 ET
|
Parion Sciences
Published Phase 2 Study findings demonstrate safety and efficacy of idrevloride in hypertonic saline for treatment of primary ciliary dyskinesiaAbstract to be presented at 2023 European Respiratory...
Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference
October 25, 2016 08:14 ET
|
Parion Sciences
DURHAM, N.C., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced that an abstract from its...
Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease
July 26, 2016 07:59 ET
|
Parion Sciences
DURHAM, N.C,, July 26, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has initiated a...
Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)
May 02, 2016 08:02 ET
|
Parion Sciences
DURHAM, N.C., May 02, 2016 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and epithelial diseases, announced today the...
Ceva and Zoion Pharma Announce Collaboration to Develop Epithelial Sodium Channel Blockers to Treat Veterinary Ocular Surface Diseases
January 19, 2016 08:00 ET
|
Parion Sciences
LIBOURNE, France and DURHAM, N.C., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Ceva Santé Animale and Zoion Pharma Inc. announced today that they have entered into a collaboration to develop an epithelial...
Parion Sciences Announces Upcoming Presentations of Data at the North American Cystic Fibrosis Conference Being Held October 8 through 10, 2015
October 05, 2015 08:12 ET
|
Parion Sciences
Data From Preclinical and Clinical Research on P-1037(VX-371) to be PresentedAdditional Data Presentation Includes a Review of a Novel in Silico Approach Towards Identification of CFTR...
CLEAN-CF Clinical Trial Expanded to Include Pediatric Cystic Fibrosis Population
September 10, 2015 09:35 ET
|
Parion Sciences
DURHAM, N.C., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that the CLEAN-CF...
Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases
June 04, 2015 16:01 ET
|
Parion Sciences
-ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development...
Parion Sciences Receives 2015 Life Sciences Award as “Best Late Stage Product Development” Company
May 22, 2015 09:28 ET
|
Parion Sciences
DURHAM, N.C., May 22, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it was awarded the...
Parion Sciences Announces Initiation of Phase 2 Clinical Study of P-1037 for the Treatment of Cystic Fibrosis
May 06, 2015 09:52 ET
|
Parion Sciences
DURHAM, N.C., May 6, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today it has begun enrollment of...